US equities |
MU $989.04 ▼-3.88% META $742.96 ▲+3.38% NVDA $226.32 ▼-1.29% SNDK $1,487.33 ▼-5.97% SPCX $163.42 ▲+0.52% MSFT $541.15 ▲+1.14% AMD $594.24 ▼-2.28% AAPL $340.97 ▲+1.29%
FinancialContent

Aridis Pharmaceuticals Inc. - Common Stock (NQ:ARDS)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 18, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aridis Pharmaceuticals Inc. - Common Stock

News headline image
Reviva Pharmaceuticals Holdings, Inc. and Aridis Pharmaceuticals, Inc. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV
Via ACCESSWIRE
News headline image
Aridis Pharmaceuticals, Inc., Genetic Technologies Limited, and American Resources Corporation Interviews to Air on the RedChip Money Report® on Bloomberg TV
Via ACCESSWIRE
News headline image
Aridis Pharmaceuticals and Rail Vision Interviews to Air on Bloomberg TV on the RedChip Money Report(R)
Via ACCESSWIRE
News headline image
FDA Provides Positive Feedback for Aridis Pharmaceuticals’ (NASDAQ: ARDS) AR-301 Phase 3 Study
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) receives encouraging input from the FDA for the proposed confirmatory Phase 3 trial of AR-301, 
Via Spotlight Growth
News headline image
Interviews with Rail Vision, Aridis Pharmaceuticals, and Digital Ally to Air on Bloomberg U.S. on the RedChip Money Report(R)
Via ACCESSWIRE
News headline image
(Updated) Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation
From Aridis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation
From Aridis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Aridis Signs Exclusive Terms to Secure Worldwide Commercial Licenses for Pan-Ebola and Pan-Marburg Monoclonal Antibody Programs from Mapp Biopharmaceutical
From Aridis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Aridis Announces a Key Milestone of Closing of Patient Enrollment in the Phase 2a Study of AR-501 in Cystic Fibrosis Patients
From Aridis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Aridis to Participate in Key Opinion Leader Discussion on Immunotherapy for Infectious Diseases
From Aridis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Aridis Pharmaceuticals Announces Third Quarter 2022 Financial Results and Business Update
From Aridis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
RedChip Interviews Aridis Pharmaceuticals' CEO Vu Truong
ORLANDO, FL / ACCESSWIRE / June 30, 2022 / RedChip Companies will air a new C-Level interview with Aridis Pharmaceuticals (NASDAQ:ARDS) on The RedChip Money Report® on Bloomberg TV, this Saturday, July... 
From RedChip
Via AccessWire
News headline image
Medical Breakthrough: CRISPR Gene Editing Technology from MIT and Harvard Phase 3: Aridis Pharmaceuticals (Nasdaq: ARDS)
NASDAQ Co. Focused on CRISPR Gene Editing Technology from the Broad Institute of MIT and Harvard: Aridis Pharmaceuticals, Inc. (Stock Symbol: ARDS) 
Via EIN Presswire